Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614948 · ClinicalTrials.gov registry record · Phase 3
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 31,835
- Enrollment target
NCT04614948: Completed Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
NCT04614948 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 31,835 participants, above the 770-participant average among 15,282 other Phase 3 trials with a reported enrollment target (4034% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04614948, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31,835 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogenicity in the different study cohorts in open-label phase.
Primary Outcome
Molecularly confirmed moderate to severe/critical COVID-19 was defined as a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positive reverse transcription/polymerase chain reaction (RT-PCR) or molecular test result from any available respiratory tract sample (example, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample. Moderate included one sign or symptom such as respiratory rate \>=20 breaths per minute (min) and symptoms such as shortness of brea
Interventions
- OTHER Placebo
- BIOLOGICAL Ad26.COV2.S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31,835 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2023-06-18 |
| Phase | Phase 3 |
What the finished NCT04614948 record still lists
NCT04614948 is an interventional study that assigns participants to a tested intervention. Its 31,835 participants enrollment target places it among the larger protocols in the corpus, above the 770-participant average among 15,282 other Phase 3 trials with a reported enrollment target (4034% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04614948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04614948 about?
NCT04614948 is a clinical study titled "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults". The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogen...
What is the current status of trial NCT04614948?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31,835 participants. The study started on 2020-11-12. Estimated completion is 2023-06-18.
What interventions are being tested in trial NCT04614948?
The interventions under investigation include: Placebo (OTHER), Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04614948?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04614948's enrollment target sits among peer trials
31,835 6th of 2000 higher than 1,995 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07282665 · 32,000 participants · Phase 3
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI